Analyst Price Targets — PYPD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 22, 2026 1:11 pm | — | Craig-Hallum | $12.00 | $3.99 | TheFly | PolyPid price target lowered to $12 from $13 at Craig-Hallum |
| July 22, 2026 10:53 am | Brandon Folkes | H.C. Wainwright | $13.00 | $3.74 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on PolyPid Ltd. (PYPD) |
| June 17, 2025 3:00 pm | Boobalan Pachaiyappan | Roth Capital | $9.00 | $3.53 | TheFly | PolyPid price target lowered to $9 from $12 at Roth Capital |
| November 4, 2024 12:26 pm | Chase Knickerbocker | Craig-Hallum | $10.00 | $3.33 | StreetInsider | Craig-Hallum Starts PolyPid Ltd. (PYPD) at Buy |
Latest News for PYPD
PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript
PolyPid NASDAQ: PYPD said its second-quarter 2026 was marked by the FDA's acceptance of its new drug application for D-PLEX100 and a commercialization agreement with Azurity Pharmaceuticals covering the United States and Canada.
FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance
PETACH TIKVA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will report its second quarter 2026 financial results and operational highlights before the open of the U.S. financial markets on…
PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company's previously communicated guidance
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PYPD.
U.S. House Trading
No House trades found for PYPD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.